Pseudomonas exotoxin has been genetically modified so that it targets
cancer cells. This was accomplished by deleting its cell binding domai
n and replacing it with Fv fragments of antibodies that react with bre
ast, colon, and other cancers. Several recombinant immunotoxins are no
w in clinical trials.